Bioactivity:

XY028-140 is a selective CDK4/CDK6 degrader. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells[1]. A375 melanoma and T47D breast cancer cells are treated with 0.3 or 1 __ XY028-140 for 24 hours. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity[1]. T47D breast cancer cells are treated with 0.03, 0.1, 0.3, 1, or 3 __ XY028-140 for 11 days. XY028-140 inhibits cancer cell proliferation in breast cancer cells[1]. [1]. Jian Jin, et al. Compositions and methods for treating cdk4/6-mediated cancer. WO2018106870A1.

CAS nr:

2229974-83-6

Purity:

98%

Molecular Weight:

760,8

SMILES:

N/A

Formula:

C39H40N10O7

Pathway:

Cell Cycle/Checkpoint

Target:

CDK